Diabetic Foot
Conditions
Brief summary
Diabetic foot complications care represent a significant burden to the Canadian healthcare system. The estimated annual expenditure in Canada for diabetic foot ulcers is more than $150 million. A small sized randomized controlled trial (n=17) investigating the use of topical oxygen therapy (n=9) against placebo (n=8) for diabetic ulcers was done recently and showed a 87% average reduction of ulcer size in treatment group versus 46% average reduction in the control group (p\<0.05). Despite the standards of care used today in diabetic foot ulcer treatment, wounds may be non-healing when they do not heal within the appropriate time frame expected by an experienced clinician. Current diabetic foot ulcer standards of care include: full medical assessment in all cases, surgical intervention where indicated and local treatment of the ulcer. Given the scarcity of controlled trials specifically designed to review the effects of topical oxygen in ulcer care, this study will contribute to the understanding of the management of these ulcers by assessing the reductions in ulcer size achieved using Natrox™ topical oxygen therapy.
Detailed description
Diabetic foot complications care represent a significant burden to the Canadian healthcare system. The estimated annual expenditure in Canada for diabetic foot ulcers is more than $150 million. Topical oxygen therapy has historically been recognized as essential for its antibiotic properties and as a nutrient. A number of studies have suggested that this method of treatment may contribute to better healing of wounds, particularly in ulcers. The Natrox™ oxygen delivery system (ODS) is a device designed to overcome a number of problems associated with previous methods of oxygen therapy by delivering continuous oxygen to the ulcer bed through a dressing. It consists of a small battery-powered oxygen concentrator which processes oxygen from air, is portable, and can be held in place by a lightweight strap. In this study, we will seek to determine the effectiveness of the Natrox™ Topical Oxygen device in patients with non-healing diabetic foot/leg ulceration in conjunction with standard best practice. The Diabetic foot ulcer standards of care include: * Full medical assessment in all cases. * Surgical operation/Intervention where indicated. * Local treatment of the ulcer (debridement followed by ulcer care according to modern ulcer healing standards and management of diabetes.) In both the treatment group and the control group, comparative changes in ulcer surface area will be measured over a period of 8 weeks to analyze wound healing.
Interventions
DEVICENatrox™ Oxygen Delivery System (ODS)
Natrox™ ODS will be applied to the subject's diabetic ulcer and attached to the active Natrox™ Oxygen Generator using the tubing provided or regular dressing will be used. The Natrox™ oxygen delivery system (ODS) is a device designed to overcome a number of problems associated with previous methods of oxygen therapy by delivering continuous oxygen to the ulcer bed through a dressing.
Sponsors
Unity Health Toronto
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Diabetic foot ulcer, which has had optimum multi-disciplinary team management for \>4 weeks 2. No planned treatment to arterial disease 3. No planned surgical intervention 4. Patients aged \>18 years. 5. Patients who understand the study, agree to adhere to the treatment and are able to give consent 6. Patients who can be followed by the same investigating team for the whole period of their participation in the study
Exclusion criteria
1. Presence of invasive infection requiring intravenous antibiotics 2. Presence of Methicillin-resistant Staphylococcus aureus (MRSA) or Pseudomonas aureus in the swab cultures 3. Pure Neuropathic ulcer with no arterial insufficiency unless they fail to heal within 12 weeks of optimum management 4. Significant reduced immunity or high dose corticosteroids (\>10mg Prednisolone) or other second line immune-suppressant 5. Need for total contact cast 6. Patients with a known sensitivity to any of the components of the evaluation device 7. Patients with known or suspected malignancy in the ulcer or surrounding tissue. 8. Patients who do not have the physical or mental capacity, or a significant other with the ability to change the Natrox™ battery pack on a daily basis 9. Patients who present with more than 10% of the ulcer surface area covered in hard eschar 10. Patients with ulcer surface area of more than 10x10cm 11. Patients who are participating in another clinical study for ulcer management 12. Patients with a known history of poor compliance with medical treatment 13. Patients who are unable to understand the aims of the study and not give informed consent 14. Pregnant female patient.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Comparative change in ulcer surface area | 8 weeks | Comparative change in ulcer surface area in the study group undergoing treatment with the NatroxTM ODS (n=10) after the 8 week treatment period. These changes in ulcer surface area will be compared to the changes measured in the control study group. |
Contacts
Primary ContactJanelle Yu, Bsc
Outcome results
None listed